Welcome to our dedicated page for Notable Labs, Ltd. Ordinary Shares news (Ticker: NTBL), a resource for investors and traders seeking the latest updates and insights on Notable Labs, Ltd. Ordinary Shares stock.
Notable Labs, Ltd. (Nasdaq: NTBL) is a clinical-stage platform therapeutics company located in Foster City, California. It specializes in developing predictive precision medicines for cancer patients through its proprietary Predictive Precision Medicines Platform (PPMP). The PPMP bio-simulates cancer treatments to predict patient responses, allowing for the identification and selection of patients who are likely to benefit from specific therapies before treatment begins. This innovative approach aims to fast-track the development of effective therapies, reducing the time, cost, and risks typically involved in drug development.
Following a notable merger with VBL Therapeutics in October 2023, Notable Labs began public trading under the symbol NTBL on the Nasdaq market. The company has been focusing heavily on advancing its PPMP platform and therapeutic pipeline targeted at cancer patients with high unmet medical needs. A significant milestone was the Phase 2a trial for Fosciclopirox, co-developed with CicloMed, which further validated the efficacy of the PPMP platform by accurately predicting patient responses.
Notable Labs is actively developing Volasertib for the treatment of acute myeloid leukemia (AML) in patients predicted to respond based on the PPMP. The company is continually expanding the application of its platform across various types of cancer and medical outcomes. With a solid financial footing, the company reported cash and cash equivalents of $14.3 million post-merger, ensuring sufficient capital to advance its projects.
The company has also been actively involved in community and research support, contributing $60,000 to the Myelodysplastic Syndrome Foundation and serving as a National Gold Sponsor for the 2023 'Move for MDS Community Walks.' These efforts illustrate Notable's commitment not only to developing cutting-edge treatments but also to supporting patient and research communities.
Notable Labs' approach represents a significant shift in the traditional drug development process, offering a targeted and de-risked strategy that aims to improve patient outcomes and commercial success rates. By transforming the standard of care, Notable Labs strives to create a dramatic, positive impact on the healthcare community and the lives of cancer patients worldwide.
For more information, visit their official website at www.notablelabs.com and follow them on social media @notablelabs.
Notable Labs (Nasdaq: NTBL) will present data on its volasertib program for acute myeloid leukemia (AML) at the Society of Hematologic Oncology (SOHO) 2024 meeting on September 4th. The presentation will provide an overview of the upcoming Phase 2 program and additional preclinical study results.
The poster, titled 'Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemia', will be presented during the poster session on Wednesday, September 4th at 6:15 PM CDT. Notable Labs, a clinical-stage precision oncology company, is developing new cancer therapies identified by its Predictive Medicine Platform (PMP).
The company expects to begin its Phase 2 volasertib AML program in the coming months, marking a significant step in the development of this potential treatment for AML patients.
Notable Labs (Nasdaq: NTBL) announced a significant leadership change as CEO Thomas A. Bock, MD, resigned from his position and the Board of Directors. Joseph Wagner, PhD, the company's Chief Scientific Officer, has been appointed as interim CEO. The Board has initiated a search for Dr. Bock's successor.
Under Dr. Bock's leadership, Notable Labs transformed from a private diagnostic start-up to a publicly-traded clinical-stage company focused on Predictive Medicine. The company remains committed to its plans, including the initiation of the Phase 2 clinical program for volasertib in the coming months. Dr. Bock will continue as a consultant, advising the Board and offering expertise on the company's next phase.
Notable Labs (NASDAQ: NTBL) has received FDA clearance to proceed with its Phase 2 study of volasertib for relapsed/refractory acute myeloid leukemia (R/R AML). The company plans to initiate patient enrollment in the coming months, following agreement on the dosing plan. The study will evaluate volasertib in combination with decitabine, utilizing Notable's Predictive Medicine Platform (PMP) to enhance patient outcomes.
The Phase 2 trial will begin with a dose optimization lead-in, incorporating body-surface area dosing and prophylactic antibiotic treatment. Notable expects initial data from this phase in Q4 2024, followed by selective enrollment of PMP-predicted responders. Initial efficacy results are anticipated in H1 2025. This progress marks a significant step in addressing the unmet need for R/R AML patients, particularly those who have received venetoclax-based therapies.
Notable Labs, a clinical-stage precision oncology company, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024. The CEO, Thomas Bock, will discuss the company's cancer therapies developed using the Predictive Medicine Platform. The event will take place on May 13-14, 2024, in New York City, with a webcast accessible on the Notable Labs website.
FAQ
What is the current stock price of Notable Labs, Ltd. Ordinary Shares (NTBL)?
What is the market cap of Notable Labs, Ltd. Ordinary Shares (NTBL)?
What does Notable Labs, Ltd. do?
Where is Notable Labs, Ltd. located?
What is the Predictive Precision Medicines Platform (PPMP)?
What recent achievements has Notable Labs accomplished?
What is Volasertib, and what is its significance?
How is Notable Labs financially positioned?
What philanthropic efforts has Notable Labs been involved in?
How does Notable Labs plan to impact the healthcare community?
When did Notable Labs begin public trading?
Where can I find more information about Notable Labs?
